Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Felbamate.

J M Pellock1

  • 1Department of Neurology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298-0211, USA.

Epilepsia
|October 26, 1999
PubMed
Summary
This summary is machine-generated.

Felbamate (FBM), an early antiepileptic drug, carries risks of aplastic anemia and liver failure. While effective, these serious side effects mean FBM is not a first-line treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative Evaluation of Medial Temporal Lobe Morphology in Children with Febrile Status Epilepticus: Results of the FEBSTAT Study.

AJNR. American journal of neuroradiology·2016
Same author

Vigabatrin 35 years later - from mechanism of action to benefit-risk considerations.

Acta neurologica Scandinavica. Supplementum·2011
Same author

Balancing clinical benefits of vigabatrin with its associated risk of vision loss.

Acta neurologica Scandinavica. Supplementum·2011
Same author

The occurrence and characteristics of auras in a large epilepsy cohort.

Acta neurologica Scandinavica·2008
Same author

Phenomenology of prolonged febrile seizures: results of the FEBSTAT study.

Neurology·2008
Same author

New developments in the treatment of epilepsy.

CNS spectrums·2008
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
Same journal

Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

Epilepsia·2026
Same journal

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia·2026
Same journal

Long-term mortality after status epilepticus: A 5-year analysis study.

Epilepsia·2026
Same journal

The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

Epilepsia·2026
Same journal

Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

Epilepsia·2026
See all related articles

Area of Science:

  • Neurology
  • Pharmacology
  • Toxicology

Background:

  • Felbamate (FBM) was an early antiepileptic drug (AED) approved in 1993 for broad-spectrum seizure control.
  • Its use was significantly limited due to severe idiosyncratic adverse effects, including aplastic anemia and hepatotoxicity.

Purpose of the Study:

  • To update information on Felbamate's idiosyncratic effects, particularly aplastic anemia and hepatotoxicity.
  • To assess the current risk profile and identify potential risk factors for Felbamate-associated adverse events.

Main Methods:

  • Review of case studies and literature concerning Felbamate-associated adverse events.
  • Estimation of the risk of aplastic anemia and hepatic failure associated with Felbamate use.

Main Results:

Related Experiment Videos

  • Thirty-four cases of Felbamate-associated aplastic anemia were reported, with 13 fatalities.
  • The estimated risk for FBM-induced aplastic anemia is significantly higher than in the general population, with prior AED hypersensitivity increasing risk.
  • Hepatic failure is less common but has affected young children; identification of a reactive metabolite and HLA studies may aid in identifying high-risk patients.

Conclusions:

  • Felbamate demonstrates broad-spectrum efficacy but carries significant risks of aplastic anemia and hepatotoxicity.
  • Specific patient factors increase the risk of these severe adverse events.
  • Despite its efficacy, Felbamate is not recommended as a first-line antiepileptic drug due to safety concerns.